EP2062570B1 - A method for obtaining stable micro-emulsions of derivatives of oxycarotenoids of short-chain organic acids, micro-emulsions obtained, and formulation which contains these - Google Patents
A method for obtaining stable micro-emulsions of derivatives of oxycarotenoids of short-chain organic acids, micro-emulsions obtained, and formulation which contains these Download PDFInfo
- Publication number
- EP2062570B1 EP2062570B1 EP07747170.4A EP07747170A EP2062570B1 EP 2062570 B1 EP2062570 B1 EP 2062570B1 EP 07747170 A EP07747170 A EP 07747170A EP 2062570 B1 EP2062570 B1 EP 2062570B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- derivatives
- oxycarotenoids
- microemulsions
- carotenoids
- zeaxanthin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
- 238000000034 method Methods 0.000 title claims description 60
- 239000000203 mixture Substances 0.000 title claims description 59
- 239000004530 micro-emulsion Substances 0.000 title claims description 31
- 150000007524 organic acids Chemical class 0.000 title claims description 5
- 235000005985 organic acids Nutrition 0.000 title claims description 4
- 238000009472 formulation Methods 0.000 title description 4
- 235000021466 carotenoid Nutrition 0.000 claims description 116
- 150000001747 carotenoids Chemical class 0.000 claims description 110
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 81
- 230000008569 process Effects 0.000 claims description 52
- 150000002632 lipids Chemical class 0.000 claims description 40
- 229960005375 lutein Drugs 0.000 claims description 39
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 39
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 38
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 38
- 235000012680 lutein Nutrition 0.000 claims description 38
- 239000001656 lutein Substances 0.000 claims description 38
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 38
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 32
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 32
- 239000001775 zeaxanthin Substances 0.000 claims description 32
- 235000010930 zeaxanthin Nutrition 0.000 claims description 32
- 229940043269 zeaxanthin Drugs 0.000 claims description 32
- 239000013078 crystal Substances 0.000 claims description 30
- 235000012658 paprika extract Nutrition 0.000 claims description 28
- 239000001688 paprika extract Substances 0.000 claims description 28
- -1 polyoxyethylene stearate Polymers 0.000 claims description 28
- 239000011159 matrix material Substances 0.000 claims description 26
- 238000002844 melting Methods 0.000 claims description 25
- 230000008018 melting Effects 0.000 claims description 25
- 150000003904 phospholipids Chemical class 0.000 claims description 22
- 239000003995 emulsifying agent Substances 0.000 claims description 20
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 18
- 239000000194 fatty acid Substances 0.000 claims description 18
- 229930195729 fatty acid Natural products 0.000 claims description 18
- 235000008210 xanthophylls Nutrition 0.000 claims description 18
- 239000004094 surface-active agent Substances 0.000 claims description 16
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 claims description 15
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 claims description 15
- 241000287828 Gallus gallus Species 0.000 claims description 15
- 238000010521 absorption reaction Methods 0.000 claims description 15
- 235000018889 capsanthin Nutrition 0.000 claims description 15
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 claims description 15
- 150000003735 xanthophylls Chemical class 0.000 claims description 15
- GVOIABOMXKDDGU-XRODXAHISA-N (3S,3'S,5R,5'R)-3,3'-dihydroxy-kappa,kappa-carotene-6,6'-dione Chemical compound O=C([C@@]1(C)C(C[C@H](O)C1)(C)C)/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C GVOIABOMXKDDGU-XRODXAHISA-N 0.000 claims description 13
- GVOIABOMXKDDGU-LOFNIBRQSA-N (3S,3'S,5R,5'R)-3,3'-dihydroxy-kappa,kappa-carotene-6,6'-dione Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C(=O)C1(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C GVOIABOMXKDDGU-LOFNIBRQSA-N 0.000 claims description 13
- GVOIABOMXKDDGU-SUKXYCKUSA-N Capsorubin Natural products O=C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C(=O)[C@@]1(C)C(C)(C)C[C@H](O)C1)\C)/C)\C)/C)[C@@]1(C)C(C)(C)C[C@H](O)C1 GVOIABOMXKDDGU-SUKXYCKUSA-N 0.000 claims description 13
- 235000009132 capsorubin Nutrition 0.000 claims description 13
- 241000282412 Homo Species 0.000 claims description 12
- 150000004665 fatty acids Chemical class 0.000 claims description 12
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 11
- 235000013793 astaxanthin Nutrition 0.000 claims description 11
- 239000001168 astaxanthin Substances 0.000 claims description 11
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 11
- 229940022405 astaxanthin Drugs 0.000 claims description 11
- KBPHJBAIARWVSC-IRHPOQNPSA-N (3R,3'S,6'R)-b,e-Carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@@H](O)CC1(C)C KBPHJBAIARWVSC-IRHPOQNPSA-N 0.000 claims description 10
- 239000007908 nanoemulsion Substances 0.000 claims description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 9
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 8
- GYZWNQLEQAGWGD-DKLMTRRASA-N Isozeaxanthin Chemical compound CC=1C(O)CCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(O)CCC1(C)C GYZWNQLEQAGWGD-DKLMTRRASA-N 0.000 claims description 8
- 229930182558 Sterol Natural products 0.000 claims description 8
- GYZWNQLEQAGWGD-LOFNIBRQSA-N all-trans-Isozeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(O)CCC1(C)C)C=CC=C(/C)C=CC2=C(C)C(O)CCC2(C)C GYZWNQLEQAGWGD-LOFNIBRQSA-N 0.000 claims description 8
- 210000002969 egg yolk Anatomy 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 8
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 8
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 8
- 235000003702 sterols Nutrition 0.000 claims description 8
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 claims description 7
- 239000004212 Cryptoxanthin Substances 0.000 claims description 7
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 7
- 235000002360 beta-cryptoxanthin Nutrition 0.000 claims description 7
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 235000019244 cryptoxanthin Nutrition 0.000 claims description 7
- 235000013345 egg yolk Nutrition 0.000 claims description 7
- 230000019612 pigmentation Effects 0.000 claims description 7
- 150000003432 sterols Chemical class 0.000 claims description 7
- 235000013311 vegetables Nutrition 0.000 claims description 7
- 235000020674 meso-zeaxanthin Nutrition 0.000 claims description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 6
- 239000013589 supplement Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 238000010348 incorporation Methods 0.000 claims description 5
- 235000021313 oleic acid Nutrition 0.000 claims description 5
- 229920001983 poloxamer Polymers 0.000 claims description 5
- 244000144977 poultry Species 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000001993 wax Substances 0.000 claims description 5
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000021323 fish oil Nutrition 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 3
- 102000002322 Egg Proteins Human genes 0.000 claims description 3
- 108010000912 Egg Proteins Proteins 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- FMPGIACYOGJFQX-CPQPWORTSA-N [(1r)-3,5,5-trimethyl-4-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohexen-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohex-3-en-1-yl] acetate Chemical compound CC1(C)C[C@H](OC(=O)C)CC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FMPGIACYOGJFQX-CPQPWORTSA-N 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 3
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 3
- 239000006014 omega-3 oil Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000000254 damaging effect Effects 0.000 claims description 2
- 229920001664 tyloxapol Polymers 0.000 claims description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 2
- 229960004224 tyloxapol Drugs 0.000 claims description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 1
- 230000036996 cardiovascular health Effects 0.000 claims 1
- 229960004488 linolenic acid Drugs 0.000 claims 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 125000002640 tocopherol group Chemical class 0.000 claims 1
- 235000019149 tocopherols Nutrition 0.000 claims 1
- 229930003802 tocotrienol Natural products 0.000 claims 1
- 239000011731 tocotrienol Substances 0.000 claims 1
- 235000019148 tocotrienols Nutrition 0.000 claims 1
- 229940068778 tocotrienols Drugs 0.000 claims 1
- 239000002888 zwitterionic surfactant Substances 0.000 claims 1
- 239000000693 micelle Substances 0.000 description 26
- 239000003921 oil Substances 0.000 description 21
- 235000019198 oils Nutrition 0.000 description 21
- 239000000839 emulsion Substances 0.000 description 19
- 239000012071 phase Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 239000000084 colloidal system Substances 0.000 description 12
- 239000006185 dispersion Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 11
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- USJBGSPHUDEYGM-ZBUGBIPZSA-N [(1r)-4-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-18-[(1r,4r)-4-acetyloxy-2,6,6-trimethylcyclohex-2-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethylcyclohex-3-en-1-yl] acetate Chemical compound CC1(C)C[C@H](OC(=O)C)CC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@@H]1C(C)(C)C[C@@H](OC(C)=O)C=C1C USJBGSPHUDEYGM-ZBUGBIPZSA-N 0.000 description 9
- 239000000787 lecithin Substances 0.000 description 9
- 235000010445 lecithin Nutrition 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 240000000785 Tagetes erecta Species 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000013019 agitation Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000136 polysorbate Polymers 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 235000015112 vegetable and seed oil Nutrition 0.000 description 7
- 239000008158 vegetable oil Substances 0.000 description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 235000012682 canthaxanthin Nutrition 0.000 description 6
- FDSDTBUPSURDBL-DKLMTRRASA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-DKLMTRRASA-N 0.000 description 6
- 229940067606 lecithin Drugs 0.000 description 6
- 239000008601 oleoresin Substances 0.000 description 6
- 229950008882 polysorbate Drugs 0.000 description 6
- 240000004160 Capsicum annuum Species 0.000 description 5
- 235000012311 Tagetes erecta Nutrition 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 150000001746 carotenes Chemical class 0.000 description 5
- 235000005473 carotenes Nutrition 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000005690 diesters Chemical class 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000005881 Calendula officinalis Nutrition 0.000 description 3
- 241000238424 Crustacea Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000277331 Salmonidae Species 0.000 description 3
- OLFXPGIJEZQMAY-JUBYCYMMSA-N [(1r)-4-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-18-[(4r)-4-acetyloxy-2,6,6-trimethylcyclohexen-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethylcyclohex-3-en-1-yl] acetate Chemical compound CC1(C)C[C@H](OC(=O)C)CC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](OC(C)=O)CC1(C)C OLFXPGIJEZQMAY-JUBYCYMMSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000002706 plastid Anatomy 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 150000004492 retinoid derivatives Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000001195 (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 235000007862 Capsicum baccatum Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- 241001282110 Pagrus major Species 0.000 description 2
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001219 Polysorbate 40 Polymers 0.000 description 2
- 229920002642 Polysorbate 65 Polymers 0.000 description 2
- 229920002651 Polysorbate 85 Polymers 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008293 association colloid Substances 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000021384 green leafy vegetables Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 235000013310 margarine Nutrition 0.000 description 2
- 239000003264 margarine Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000006241 metabolic reaction Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000243 photosynthetic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000000485 pigmenting effect Effects 0.000 description 2
- 239000001194 polyoxyethylene (40) stearate Substances 0.000 description 2
- 235000011185 polyoxyethylene (40) stearate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 2
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 2
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229940101027 polysorbate 40 Drugs 0.000 description 2
- 229940099511 polysorbate 65 Drugs 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229940113171 polysorbate 85 Drugs 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- RAFGELQLHMBRHD-VFYVRILKSA-N Bixin Natural products COC(=O)C=CC(=C/C=C/C(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C(=O)O)/C)C RAFGELQLHMBRHD-VFYVRILKSA-N 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- YHGJHDJZIOYZIR-URPSFYETSA-N Helenien Chemical compound CC1(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@@H]1C(C)(C)C[C@@H](OC(=O)CCCCCCCCCCCCCCC)C=C1C YHGJHDJZIOYZIR-URPSFYETSA-N 0.000 description 1
- YHGJHDJZIOYZIR-KFTCWRDFSA-N Helenien Natural products O=C(O[C@H]1C=C(C)[C@H](/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=2C(C)(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC=2C)\C)/C)\C)/C)C(C)(C)C1)CCCCCCCCCCCCCCC YHGJHDJZIOYZIR-KFTCWRDFSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- UNTSJRBZLAUZBX-CMKMZYONSA-N Methyl bixin Natural products O=C(OC)/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(\C=C\C(=O)OC)/C)/C)\C)/C UNTSJRBZLAUZBX-CMKMZYONSA-N 0.000 description 1
- 229920006197 POE laurate Polymers 0.000 description 1
- XACHQDDXHDTRLX-XLVVAOPESA-N Physalien Chemical compound CC1(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](OC(=O)CCCCCCCCCCCCCCC)CC1(C)C XACHQDDXHDTRLX-XLVVAOPESA-N 0.000 description 1
- XACHQDDXHDTRLX-GMPBGBGESA-N Physalien Natural products O=C(O[C@H]1CC(C)(C)C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=2C(C)(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC=2C)\C)/C)\C)/C)=C(C)C1)CCCCCCCCCCCCCCC XACHQDDXHDTRLX-GMPBGBGESA-N 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- XACHQDDXHDTRLX-UHFFFAOYSA-N Zeaxanthin-dipalmitat Natural products CC1(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC1(C)C XACHQDDXHDTRLX-UHFFFAOYSA-N 0.000 description 1
- XRASMHAVNYGCPS-QJJJVGGWSA-N [(1r)-4-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-19-[(1r,4s)-4-acetyloxy-1,2,2-trimethylcyclopentyl]-3,7,12,16-tetramethyl-19-oxononadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethylcyclohex-3-en-1-yl] acetate Chemical compound C1[C@@H](OC(=O)C)CC(C)(C)[C@]1(C)C(=O)\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](OC(C)=O)CC1(C)C XRASMHAVNYGCPS-QJJJVGGWSA-N 0.000 description 1
- SAMLPFAHRYIYAW-UFALDXFJSA-N [(1r)-4-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-19-[(1r,4s)-4-hexadecanoyloxy-1,2,2-trimethylcyclopentyl]-3,7,12,16-tetramethyl-19-oxononadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethylcyclohex-3-en-1-yl] hexadecanoate Chemical compound C1[C@@H](OC(=O)CCCCCCCCCCCCCCC)CC(C)(C)[C@]1(C)C(=O)\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](OC(=O)CCCCCCCCCCCCCCC)CC1(C)C SAMLPFAHRYIYAW-UFALDXFJSA-N 0.000 description 1
- HDLNSTQYXPTXMC-MJSVCVTMSA-N [(1s)-4-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-18-[(4s)-4-acetyloxy-2,6,6-trimethyl-3-oxocyclohexen-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-2-oxocyclohex-3-en-1-yl] acetate Chemical compound O=C1[C@@H](OC(=O)C)CC(C)(C)C(\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=2C(C[C@@H](C(=O)C=2C)OC(C)=O)(C)C)=C1C HDLNSTQYXPTXMC-MJSVCVTMSA-N 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 108010058834 acylcarnitine hydrolase Proteins 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- YHGJHDJZIOYZIR-UHFFFAOYSA-N all-trans-lutein dipalmitate Natural products CC1(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1C(C)(C)CC(OC(=O)CCCCCCCCCCCCCCC)C=C1C YHGJHDJZIOYZIR-UHFFFAOYSA-N 0.000 description 1
- RAFGELQLHMBRHD-UHFFFAOYSA-N alpha-Fuc-(1-2)-beta-Gal-(1-3)-(beta-GlcNAc-(1-6))-GalNAc-ol Natural products COC(=O)C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC(O)=O RAFGELQLHMBRHD-UHFFFAOYSA-N 0.000 description 1
- 239000001670 anatto Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 235000012665 annatto Nutrition 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- MQZIGYBFDRPAKN-UWFIBFSHSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-UWFIBFSHSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- RAFGELQLHMBRHD-SLEZCNMESA-N bixin Chemical compound COC(=O)\C=C\C(\C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C(O)=O RAFGELQLHMBRHD-SLEZCNMESA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthine Natural products CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000004491 dispersible concentrate Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 244000038280 herbivores Species 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 150000002646 long chain fatty acid esters Chemical class 0.000 description 1
- 125000002635 lutein group Chemical group 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020912 omnivore Nutrition 0.000 description 1
- 244000054334 omnivore Species 0.000 description 1
- 239000001053 orange pigment Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000001959 sucrose esters of fatty acids Substances 0.000 description 1
- 235000010965 sucrose esters of fatty acids Nutrition 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000002978 thoracic duct Anatomy 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- UNTSJRBZLAUZBX-VBBCTIIMSA-N trans-Methylbixin Chemical compound COC(=O)\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C(=O)OC UNTSJRBZLAUZBX-VBBCTIIMSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
- Y02A40/818—Alternative feeds for fish, e.g. in aquacultures
Definitions
- the present invention is related to a process that noticeably improves the bioavailability of carotenoids by obtaining carotenoids micelles in a lipid matrix in the presence of water.
- lipid matrix is composed of the free fatty acids, to which the xanthophylls are naturally bound, and the waxes, phospholipids and sterols that naturally occur in the carotenoids extracts, as well as emulsifying agents.
- lutein, zeaxanthin, and other carotenoids with short chain organic acids like acetic or propionic acids and further processing it occurs the formation of carotenoids micelles in a lipid matrix that have been found to be readily absorbed through the intestine wall.
- the invention also relates to formulations of carotenoid microemulsions and nanoemulsions that improve the bioavailability in humans, poultry and marine organisms.
- Carotenoids are terpenoid compounds that besides their typical pigmenting characteristics (yellow, orange or red pigments), function as precursors of molecules with biological activity intervening in different vital biological and physiological processes.
- Carotenoids are classified in two major groups: carotenes, which are hydrocarbon molecules comprising atoms of carbon and hydrogen only. Representative examples of carotenes include ß-Carotene and Lycopene. And xanthophylls, which are oxygenated derivatives of the carotenes. Examples of xanthophylls include Lutein, Zeaxanthin, Isozeaxanthin, Capsanthin, Capsorubin, Cryptoxanthin, Astaxanthin, 3' Epilutein, and Cantaxanthin.
- Carotenoids are widely distributed in nature. Total annual production in nature is estimated at over 100 million tons. Carotenoids intervene in the physiology of all living organisms. They are produced in nature by photosynthetic and enzymatic reactions carried by marine microorganisms as microalgae, bacteria, fungii and zooplancton; and in most terrestrial living plants occur in leaves, flowers and fruits.
- carotenoids are more abundant than in terrestrial organisms and they are responsible for several vital biological, physiological, metabolic and reproductive functions. Carotenoids provide color to marine microalgae and bacteria, krill, salmon, trout, red sea bream, yellow tail tuna, crustaceans etc.
- Broilers and layers grown in captivity require a given dose of lutein and zeaxanthin in their feed in order to supplement their requirements.
- Laying hens accumulate lutein, zeaxanthin and cantaxanthin in the yolk, protecting the embryo against the oxidative damage provoked by the free radicals that occur due to the high rate of metabolic reactions in the rapidly developing embryo.
- Broilers on the other hand, accumulate lutein and zeaxanthin in their adipose tissue as well as in the skin. Such deposits act as reservoirs of carotenoids, and become available when required to perform specific physiological functions.
- carotenoids are metabolized by terrestrial or marine organism into Vitamin A, and such carotenoids are the only source of Vitamin A for herbivores or omnivores living in their natural environment.
- Carotenoids act as effective antioxidants in most living organisms. They have the capability to quench free radicals that are produced in metabolic reactions at cellular level, avoiding tissue degradation.
- Lutein and Zeaxanthin are also present in human breast milk, and in the adipose tissues.
- Carotenoids occur in a concentrated way in chromoplasts attached to proteins or fibers by non-covalent links. However, chloroplast or chromoplast and other plant structural materials may not be the ideal source of carotenoids for human consumption due to their low bioavailability. Carotenoids occur in food plants as part of the photosynthetic apparatus (green leafy vegetables), dissolved in oil droplets (fruits) or as semi crystalline membrane-bound solids (carrot, tomato).
- Fatty acid esters of carotenoids such as lutein, zeaxanthin and cryptoxanthin, occur in some fruits (peaches, papaya, peppers), as well as in xanthophyll concentrates obtained from marigold ( Tagetes erecta ) and red peppers ( Capsicum annum ).
- carotenoids In order that the carotenoids are absorbed by the organism they should previously be freed from their chromoplast matrix. They are thought to be hydrolyzed in the intestinal lumen before mucosal uptake, most likely by the carboxylic ester hydrolase secreted by the pancreas.
- the carotenoids After the carotenoids are absorbed, they are transported through the enterocytes from the luminal side to the serosal side. They are packaged in chylomicrons and secreted into the thoracic duct, and find their way into the circulating blood via the vena cava inferior.
- emulsion based food product with quality attributes depends on the selection of the most appropriate raw materials (e.g., water, oil, emulsifier, thickening agents, minerals, acids, colorants, flavours, vitamins, etc.) and processing conditions(e.g.- mixing, homogenization, pasteurizations, sterilization, etc.).
- raw materials e.g., water, oil, emulsifier, thickening agents, minerals, acids, colorants, flavours, vitamins, etc.
- processing conditions e.g.- mixing, homogenization, pasteurizations, sterilization, etc.
- An emulsion is a mixture of two immiscible liquids (usually oil and water), with one of them dispersed as small spherical droplets in the other phase. Emulsions can be conveniently classified according to the distribution of the oil and aqueous phases.
- a system which consist of oil droplets dispersed in an aqueous phase is called an oil-in-water or O/W emulsion (e.g., mayonnaise, milk, cream, soups and sauces).
- a system which consists of water droplets dispersed in an oil phase is called a water-in oil or W/O (e.g., margarine, butter and spreads).
- Emulsions are part of a more general class of two-phase systems of matter called colloid.
- emulsion tends to imply that both the dispersed and the continuous phase are liquid.
- An emulsifier also known as a surfactant from surface active material or emulgent
- emulsifier is a substance which stabilizes an emulsion.
- the main role of the surfactants in food emulsions is to enhance their formation and stability.
- Surfactants used in the food industry are mainly nonionic (e.g., monoacylglycerols, sucrose esters of fatty acids), anionic (e.g., fatty acids), or zwitterionic (e.g., lecithin).
- association colloids e.g., micelles, bilayers, vesicles, and reverse micelles.
- the shape of a micelle is controlled largely by the molecular geometry of its surfactant molecules, but micelle shape also depends on the conditions (such as temperature or pH, and the type and concentration of any added salt).
- Nonpolar molecules which are normally insoluble or only sparingly soluble in water, can be solubilized in an aqueous surfactant solution by incorporation into micelles or other types of association colloids.
- Micelles containing solubilizied materials are referred to as microemulsions or swollen micelles whereas the materials solubilizied within the micelle referred to as the solubilizate.
- US Patent 2,861,891 issued to Bauernfeind and Howard describes a process to obtain a dry powder, obtaining a supersaturated carotene solution by heating in a vegetable oil that afterwards is dispersed in an aqueous gelable colloid solution, and converting the emulsion thus formed into a dry particulate form.
- Such process involves heating the carotenoids in vegetable oil in order to improve the solubility of the carotenes, lycopene, lutein, zeaxanthin, cryptoxanthin, bixin and methyl bixin, and avoiding the precipitation of carotenoids crystals by incorporating a gelable colloid.
- a further emulsification step follows in an aqueous colloidal solution that forms a gel capable of producing a dry powder after a spray drying process.
- the product obtained is a microcrystalline dispersion in edible oil used to impart color to margarine, fruits and vegetables in which the ⁇ carotene occurs in the form of microdispersion in a protective hydrophilic colloid.
- Cathrein describes in US Patent 5,364,563 a process for producing powdered carotenoid preparations by obtaining a suspension in oil that is brought in contact with superheated steam, producing an emulsion that is spray dried.
- Eugster et al, in US Patents 5,496,813 and 5,536,504 obtain ultra microemulsions that form spontaneously dispersible concentrates containing xanthophylls esters that have anti tumor activity.
- Luddecke, et al, in US Patent 5,863,953 describes the obtention of an oil dispersion of carotenoids, which is used to prepare a double dispersion system with particles sizes of 100 microns, stabilized by a protective colloid and emulsifiers.
- Kolter et al describe in US Patent 5,891,907 stable aqueous solubilizates of carotenoids and vitamins, in which the carotenoids and the water insoluble vitamins with the aid of a nonionic emulsifier, yield a micelle, which particles are smaller than 100 nm.
- Schweikert et al in US Patent 5,925,684 describe a stable oil in water emulsion consisting of an aqueous phase and an oil phase which is very finely dispersed by means of an emulsifier, and wherein the carotenoid is present in the oil phase in a concentration above the saturation solubility of the carotenoid in the oil at room temperature.
- Auweter et al describe in US Patent 5,968,251 the preparation of coldwater dispersible powders by preparing a molecular-disperse solution of a carotenoid, with or without an emulsifier and/or edible oil, in a volatile, water-miscible organic solvent at elevated temperature and adding an aqueous solution of a protective colloid; whereupon the hydrophilic solvent is transferred into the aqueous phase, and the hydrophobic phase of the carotenoid results as a nanodisperse phase, removing the solvent by heating the hydrosol and converting it in a water dispersible dry powder.
- Handelman in US Patent 6,075,058 describes the composition of lutein and zeaxanthin along with cholesterol, olive oil, egg yolk phospholipids, alpha tocopherol and aqueous sodium chloride.
- the mixture is prepared by mixing the lipid ingredients into ethanol, evaporating the ethanol, and dispersing the lipids as an emulsion in the sodium chloride solution.
- Bewert et al, in US Patent 6,328,995 describe a procedure to stabilize dry powders which are insoluble in hot water and which contain one or more lipid soluble vitamins or carotenoids, formed in an aqueous dispersion containing a protein, a sugar and potassium and/or sodium phosphates.
- US-5,959,138 discloses a process to obtain a product having a high content of zeaxanthin, lutein or mixtures thereof, as short chain organic acid diesters of zeaxanthin, lutein or mixtures thereof, that can be used mainly for the pigmentation of broilers and egg yolks, as well as an intermediate in the cantaxanthin ( ⁇ , ⁇ -Carotene-4,4'-dione) and astaxanthin (3,3'-Dihydroxy- ⁇ , ⁇ -carotene,4,4'-dione) synthesis, by reacting extracts obtained from marigold (Tagetes Erecta L.), or plant extracts that contain lutein, zeaxanthin or mixtures thereof in any proportion, with acetic or propionic anhydride under controlled conditions of temperature and pressure.
- the products obtained in US-5,959,138 may be used in the present process.
- microemulsions or nanoemulsions of lutein, 3'epilutein, and zeaxanthin diacetates and dipropionates as well as short chain diesters of capsanthin, capsorubin, astaxantin and the acetate and propionate of cryptoxanthin that readily form micelles that are absorbed in the gut and diffuse through the mucous intestine wall.
- Crystalline solids are composed of atoms, ions, or molecules in a highly ordered geometric pattern (the crystal lattice).
- the atoms, ions or molecules are held in their positions by electrostatic, dipole and/or London forces.
- electrostatic, dipole and/or London forces When a pure crystalline solid is heated, the atoms, ions or molecules vibrate more and more rapidly until at a definite temperature the thermal motion of the particles becomes great enough to overcome the forces of attraction. Then the atoms, ions or molecules enter a more random and mobile state, the liquid state.
- the melting point of a solid is defined as the temperature at which the liquid and solid phases are in equilibrium. A pure solid will generally melt sharply because the forces of attraction between the particles are the same.
- Such hydrolysis is carried out either in an aqueous media by means of a strong alkali and suitable emulsifiers and temperature, or in a non polar organic media like propylene glycol, also under the action of a strong alkali and temperature. In both cases, as the xanthophylls are free they become insoluble in the reaction media and occur in crystalline form.
- the reaction mass can be used to prepare pigment premixes or water dispersions, but the physical structure of the carotenoids is always microscopic crystals.
- the saponified oleoresin mass is subject to several stages of selective organic polar, or non polar solvent extractions, or supercritical CO 2 extractions, and recrystallizations in order to isolate the carotenoids from the other components of the mass.
- the carotenoids as expected, occur in crystalline form.
- the micelles, microemulsions and nanoemulsions of oxycarotenoids derivatives are obtained during the reaction of such oxycarotenoids with short chain organic acids like acetic or propionic acid.
- Such microscopic emulsions occur during the course of such reaction under controlled conditions and further processing.
- the carotenoids derivatives obtained by this process do have melting points that are lower as compared to the melting points of the free carotenoids.
- the carotenoid derivatives crystals under certain conditions of temperature, time, and in the presence of lipids, emulsifiers, and moisture, form stable micelles occluded in the lipid matrix and remain as such at normal conditions of temperature and pressure.
- Such lipid carotenoid micelles contain melt down oxycarotenoids derivatives, and are non-crystalline.
- the patent also discloses a process for the preparation of microemulsions and micelles and its uses in administering lutein and zeaxanthin diacetates or dipropionates, and those of other oxycarotenoids derivatives to humans, as well as for the pigmentation of broilers, egg yolks, and marine species as salmonids, crustaceans and fish.
- microemulsions obtained can be reduced in size to obtain nanoemulsions by intense high speed and high shear mechanical agitators for a period of 3 to 4 hours, or by emulsifying machines operating at pressures of the order of 3,000 to 4,000 psi.
- microemulsions obtained in step h) may be dispersed in an aqueous or lipid media, suitable to be incorporated in human supplements or foods, or feeds for pets, poultry or aquatic animals at a temperature of between about 40 to 70o C in order to, among other applications: noticeably improving the absorption and bioavailability of xanthophylls diacetates and dipropionates obtained from lutein, zeaxanthin, capsanthin and capsorubin, for the purpose of pigmentation of broilers skin and egg yolks or improving the bioavailability of the carotenoids derivatives obtained from: lutein, zeaxanthin, capsanthin, capsorubin, and astaxanthin when incorporated in the feed of marine organisms such as shrimp and crustaceans, salmon, trout, red sea bream, yellow tail tuna.
- the aqueous or lipid media microemulsions dispersion may comprise: water containing carotenoids derivatives obtained from the following carotenoids: lutein, 3'epilutein, zeaxanthin, isozeaxanthin, mesozeaxanthin, capsanthin, capsorubin, astaxanthin and cryptoxanthin, which can be administered to humans as a supplement to prevent the degeneration of human tissues due to the presence of free radicals; or oil, preferebly fish oil with a high content of omega 3 fatty acids, containing carotenoids derivatives which noticeably improves the bioavailability of oxycarotenoid derivatives like lutein, 3'epilutein, zeaxanthin, meso zeaxanthin, iso zeaxanthin, capsanthin, capsorubin and astaxanthin diacetates or dipropionates in humans which can be administered to humans as a supplement to prevent and protect cells and tissues from the damaging effects of
- microemulsion of carotenoids derivatives obtained from: lutein, 3'epilutein, zeaxanthin, iso zeaxanthin, meso zeaxanthin, capsanthin, capsorubin, and astaxanthin obtained in step h) may also be encapsulated by suitable maltodextrins; sugars; animal, vegetable or fish gelatins in order to prepare beadlets for supplementing the nutrition of humans.
- the above described process helps the dissolution of crystals and avoids the oxycarotenoids derivatives contained in the original matrix to recrystallize at room temperature.
- carotenoids are unstable and tend to degrade when exposed to light, oxygen and organic or inorganic acids at elevated temperatures. While processing carotenoids under such conditions all operations should be performed either under vacuum or under an inert atmosphere such as a nitrogen atmosphere. It was observed a remarkable stability of the short chain diester oxycarotenoids, namely diacetates or dipropionates, after being subject to such conditions.
- the diacetate and the dipropionates are derivatives of carotenoids of non polar nature, they tend to melt down and remain as micro or nanospheres dispersed in the lipid matrix at a lower temperature than the melting point of the pure carotenoids.
- the carotenoids derivatives crystals By increasing the temperature to 90-110 °C under agitation and under an inert atmosphere, the carotenoids derivatives crystals are melted down in the lipid non polar matrix producing a homogeneous phase. Although the melting points of pure carotenoids crystals are high; we observed that the original composition of the matrix and the incorporation of moisture, vegetable oil, additional fatty acids and emulsifiers, as well as a suitable control of the pH media during the melting process, they interact with the carotenoids crystals provoking in situ a sensible decrease of the melting point of the oxycarotenoids derivatives, producing a dispersion of non-crystalline nanoparticles of carotenoids in micellar form with average particle sizes of 2-5 nanometers.
- the present process generates oxycarotenoid derivatives that interact with the components of the matrix and at the given conditions of temperature, time and agitation, produce carotenoids compounds in a non-crystalline state that upon their incorporation in micelles notably improve their absorption and bioavailability.
- the micelles obtained can be diluted with more lipid material.
- lipid material may comprise one or more members selected from the group consisting of vegetable oil, mineral oil, medium chain tryglicerides (MCT) oil (i.e. a triglyceride oil in which the carbohydrate chain has about 8-12 carbon atoms), oily fatty acids, isopropyl myristate, oily fatty alcohols, esters of sorbitol and fatty acids, oily sucrose esters or mixtures thereof.
- MCT medium chain tryglicerides
- Examples of phospholipids which may be used in the emulsions of the invention are soy lecithins, lecithins; Epikuron 120 TM which is a mixture of about 70% phosphatidylcholine and 12% phosphatidylethanolamine and about 15% other phospholipids; Ovothin 160 TM or Ovothin 200 TM . Phosphatidylcholine, 18% phosphatidylethanolamine and 12% other phospholipids; a purified phospholipid mixture, e.g.
- An impure solid compound melts at a lower temperature and over a wider range.
- a solid's compound's melting point may be lowered (depressed) by the addition of a soluble material to the solution.
- the melting points of the pure carotenoids are higher in regard to the melting points of their corresponding derivatives. Therefore in the process to obtain carotenoids derivatives from pure carotenoids, the melting point of oxycarotenoids is reduced from 50 to 116° C with respect to the melting point of the pure carotenoid, when the diacetate derivatives are incorporated in the process; and the melting point of oxycarotenoids is reduced from 30 to 50° C with respect to the melting point of the pure carotenoid, when propionate derivatives are incorporated in the process. As the molecular weight of the carotenoid derivative is larger, then the melting point of such derivative is further reduced, as compared to the melting point of the pure carotenoid.
- the obtained micelles can be easily dispersed in water, forming stable microemulsions or nanoemulsions, composed of an internal homogeneous lipophilic phase of carotenoids derivatives that do not contain any crystals, and an external hydrophylic phase formed by lipids and emulsifiers. It is a true oxycarotenoid derivatives solute contained in the micelles. Due to its soft nature such lipid carotenoid derivatives can be easily micronized by means of a homogenizing machine into a microemulsion or a nanoemulsion. Crystalline structures per se are hard to break by mechanical means and therefore are very difficult to be worked into microemulsions and almost impossible to produce nanoemulsions in a non polar media.
- the pigmentation efficiency is noticeably improved as compared to the pigmentation obtained by premixes or water dispersions that contain the oxycarotenoids in crystalline form.
- the oxycarotenoids derivatives described in the process of the present invention may be obtained by the following process:
- the lipid matrix is incorporated in a suitable reactor under agitation, an amount of 1 kg of a vegetable oil or fish oil, fatty acid and an emulsifier mixture is added.
- the vessel is kept under a nitrogen atmosphere and the temperature is risen to 60-70°C
- the temperature of the reactor is increased to 100° C until all of the lutein diacetate crystals disappear, as can be observed under a 100X microscope objective.
- the mass is immediately cooled down to room temperature and 2 kgs of water are added under agitation to obtain a colloidal suspension.
- the above procedure is carried in a closed vessel in the absence of light and under an atmosphere of nitrogen. This procedure helps the dissolution of crystals and avoids the oxycarotenoids derivatives contained in the original matrix to recrystallize at room temperature.
- the colloid solution is ready to be dispersed in solid carriers or emulsified in water to the desired concentration.
- the oxycarotenoids derivatives described in the process of the present invention may be obtained by the following process:
- the lipid matrix is incorporated in a suitable reactor under agitation, an amount of 500 gr of oleic acid.
- the vessel is kept under a nitrogen atmosphere and the temperature is risen to 60-70°C .
- the temperature of the reactor is increased to 95° C until all of the carotenoids diacetate crystals disappear, as can be observed under a 100X microscope objective.
- the mass is immediately cooled down to room temperature and 2 kgs of water are added under agitation to obtain a colloidal suspension.
- the above procedure is carried in a closed vessel in the absence of light and under an atmosphere of nitrogen. This procedure helps the dissolution of crystals and avoids the oxycarotenoids derivatives contained in the original matrix to recrystallize at room temperature.
- the colloid solution is ready to be dispersed in solid carriers or emulsified in water to the desired concentration.
- the oxycarotenoids derivatives described in the process of the present invention may be obtained by the following process:
- the mass is rinsed several times with lukewarm water several times to remove any acid traces and salts.
- the vessel is kept under a nitrogen atmosphere and the temperature is risen to 60-70°C .
- the temperature is raised to 100°C under an atmosphere of nitrogen for a period of 180 minutes until no carotenoids crystals are observed under a 100X microscope objective.
- the colloidal suspension can be dispersed in solid carriers, vegetable oils or diluted in water.
- Group A and Group B Two identical groups (Group A and Group B) of three weeks old broilers were placed in suitable pens, containing 50 chicken each. They were fed identical feeds (ad-libitum) containing different pigmenting concentrates.
- Group A broilers feed contained 80 ppm of a blend of micellar lutein diacetate and micellar zeaxanthin diacetate prepared according to example 1.
- Group B broilers feed contained 90 ppm of a standard lutein pigment (saponified and dispersed in water) plus 3 grams of cantaxanthin.
- a Minolta Chromameter was used to determine the pigment reading in the breast skin of each refrigerated broiler.
- the average readings obtained for each group are as follows: Group Yellowness (b*) Redness (a*) Luminosity A 27.12 -1.19 76.12 B 26.21 0.90 74.09
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Insects & Arthropods (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Fodder In General (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Feed For Specific Animals (AREA)
Description
- The present invention is related to a process that noticeably improves the bioavailability of carotenoids by obtaining carotenoids micelles in a lipid matrix in the presence of water. Such lipid matrix is composed of the free fatty acids, to which the xanthophylls are naturally bound, and the waxes, phospholipids and sterols that naturally occur in the carotenoids extracts, as well as emulsifying agents. During the esterification reaction of lutein, zeaxanthin, and other carotenoids with short chain organic acids like acetic or propionic acids and further processing, it occurs the formation of carotenoids micelles in a lipid matrix that have been found to be readily absorbed through the intestine wall. Such absorption is a noticeable improvement as compared to the lower bioavailability of carotenoid crystals. The invention also relates to formulations of carotenoid microemulsions and nanoemulsions that improve the bioavailability in humans, poultry and marine organisms.
- Carotenoids are terpenoid compounds that besides their typical pigmenting characteristics (yellow, orange or red pigments), function as precursors of molecules with biological activity intervening in different vital biological and physiological processes.
- Over 600 different carotenoids have been recognized in nature. Carotenoids are classified in two major groups: carotenes, which are hydrocarbon molecules comprising atoms of carbon and hydrogen only. Representative examples of carotenes include ß-Carotene and Lycopene. And xanthophylls, which are oxygenated derivatives of the carotenes. Examples of xanthophylls include Lutein, Zeaxanthin, Isozeaxanthin, Capsanthin, Capsorubin, Cryptoxanthin, Astaxanthin, 3' Epilutein, and Cantaxanthin.
- Carotenoids are widely distributed in nature. Total annual production in nature is estimated at over 100 million tons. Carotenoids intervene in the physiology of all living organisms. They are produced in nature by photosynthetic and enzymatic reactions carried by marine microorganisms as microalgae, bacteria, fungii and zooplancton; and in most terrestrial living plants occur in leaves, flowers and fruits.
- In flowers and fruits carotenoids impart vivid yellow, orange and red colors.
- In birds carotenoids play the role of vital functions as well as cosmetic purposes, they differentiate genders, and are indicative of sexual maturity and attraction.
- In marine organism carotenoids are more abundant than in terrestrial organisms and they are responsible for several vital biological, physiological, metabolic and reproductive functions. Carotenoids provide color to marine microalgae and bacteria, krill, salmon, trout, red sea bream, yellow tail tuna, crustaceans etc.
- No animal species are capable of synthesizing carotenoids. Therefore, they should obtain their requirements through the diet. Broilers and layers grown in captivity require a given dose of lutein and zeaxanthin in their feed in order to supplement their requirements. Laying hens accumulate lutein, zeaxanthin and cantaxanthin in the yolk, protecting the embryo against the oxidative damage provoked by the free radicals that occur due to the high rate of metabolic reactions in the rapidly developing embryo. Broilers, on the other hand, accumulate lutein and zeaxanthin in their adipose tissue as well as in the skin. Such deposits act as reservoirs of carotenoids, and become available when required to perform specific physiological functions.
- Some carotenoids are metabolized by terrestrial or marine organism into Vitamin A, and such carotenoids are the only source of Vitamin A for herbivores or omnivores living in their natural environment.
- Carotenoids act as effective antioxidants in most living organisms. They have the capability to quench free radicals that are produced in metabolic reactions at cellular level, avoiding tissue degradation.
- Extensive research in the past years indicate that the presence of Lutein and Zeaxanthin in the macula helps the prevention of age related macular degeneration in humans, as well as avoids the development of cataracts. Lutein and Zeaxanthin are also present in human breast milk, and in the adipose tissues.
- Dark green leafy vegetables, tomatoes, as well as yellow corn, and many fruits like oranges, mangoes, grapefruit, etc. are the natural source of dietary carotenoids. Carotenoids occur in a concentrated way in chromoplasts attached to proteins or fibers by non-covalent links. However, chloroplast or chromoplast and other plant structural materials may not be the ideal source of carotenoids for human consumption due to their low bioavailability. Carotenoids occur in food plants as part of the photosynthetic apparatus (green leafy vegetables), dissolved in oil droplets (fruits) or as semi crystalline membrane-bound solids (carrot, tomato). Fatty acid esters of carotenoids, such as lutein, zeaxanthin and cryptoxanthin, occur in some fruits (peaches, papaya, peppers), as well as in xanthophyll concentrates obtained from marigold (Tagetes erecta) and red peppers (Capsicum annum).
- In order that the carotenoids are absorbed by the organism they should previously be freed from their chromoplast matrix. They are thought to be hydrolyzed in the intestinal lumen before mucosal uptake, most likely by the carboxylic ester hydrolase secreted by the pancreas.
- In animals, the absorption of carotenoids is generally accepted to follow that of lipids- i.e. emulsification and incorporation into mixed micelles, which are then absorbed by the mucosa of the small intestine, mainly in the duodenum, in parallel with fat digestion and absorption. They are transported through the unstirred water layer and taken up by the enterocytes by passive diffusion.
- It is in the intestine mucous wall that such passive diffusion is improved if the carotenoids are dissolved in a lipid forming a micelle in an aqueous media, rather than if they are in crystalline form. Crystals are not the ideal physical form for this diffusion to occur, nor are carotenoids crystals readily incorporated into micelles. If the carotenoids enter the gut already as microemulsions, or as nanoemulsions, the formation of micelles is facilitated.
- After the carotenoids are absorbed, they are transported through the enterocytes from the luminal side to the serosal side. They are packaged in chylomicrons and secreted into the thoracic duct, and find their way into the circulating blood via the vena cava inferior.
- Among the main factors that affect the bioavailability of xanthophylls by organisms are: physical form in the source (food matrix), the structure of the xanthophylls molecules, and the interaction of the xanthophylls with other nutrients, mainly lipids. Therefore, it would be highly desirable to develop carotenoids compounds, derivatives or formulations with improved stability, absorption and bioavailability.
- Many natural and processed foods consist either partly or wholly as emulsions or have been in an emulsified state at some time during their production. The manufacture of an emulsion based food product with quality attributes depends on the selection of the most appropriate raw materials (e.g., water, oil, emulsifier, thickening agents, minerals, acids, colorants, flavours, vitamins, etc.) and processing conditions(e.g.- mixing, homogenization, pasteurizations, sterilization, etc.).
- An emulsion is a mixture of two immiscible liquids (usually oil and water), with one of them dispersed as small spherical droplets in the other phase. Emulsions can be conveniently classified according to the distribution of the oil and aqueous phases. A system which consist of oil droplets dispersed in an aqueous phase is called an oil-in-water or O/W emulsion (e.g., mayonnaise, milk, cream, soups and sauces). A system which consists of water droplets dispersed in an oil phase is called a water-in oil or W/O (e.g., margarine, butter and spreads). Emulsions are part of a more general class of two-phase systems of matter called colloid. Although the terms colloid and emulsion are sometimes used interchangeably, emulsion tends to imply that both the dispersed and the continuous phase are liquid. An emulsifier (also known as a surfactant from surface active material or emulgent) is a substance which stabilizes an emulsion. The main role of the surfactants in food emulsions is to enhance their formation and stability. Surfactants used in the food industry are mainly nonionic (e.g., monoacylglycerols, sucrose esters of fatty acids), anionic (e.g., fatty acids), or zwitterionic (e.g., lecithin). Surfactants aggregate spontaneously in solution to form a variety of thermodynamically stable structures know as association colloids (e.g., micelles, bilayers, vesicles, and reverse micelles). The shape of a micelle is controlled largely by the molecular geometry of its surfactant molecules, but micelle shape also depends on the conditions (such as temperature or pH, and the type and concentration of any added salt).
- Nonpolar molecules, which are normally insoluble or only sparingly soluble in water, can be solubilized in an aqueous surfactant solution by incorporation into micelles or other types of association colloids. Micelles containing solubilizied materials are referred to as microemulsions or swollen micelles whereas the materials solubilizied within the micelle referred to as the solubilizate.
- In view of the above referred needs, applicants developed a process for obtaining a microscopic physical state of xanthophylls or oxycarotenoids derivatives forms such as diacetates and dipropionates derivatives that are readily incorporated in the digestive system as micelles providing an improved bioavailabilty, as compared to the bioavailability of carotenoids that are ingested in crystalline form.
-
US Patent 2,861,891 issued to Bauernfeind and Howard describes a process to obtain a dry powder, obtaining a supersaturated carotene solution by heating in a vegetable oil that afterwards is dispersed in an aqueous gelable colloid solution, and converting the emulsion thus formed into a dry particulate form. Such process involves heating the carotenoids in vegetable oil in order to improve the solubility of the carotenes, lycopene, lutein, zeaxanthin, cryptoxanthin, bixin and methyl bixin, and avoiding the precipitation of carotenoids crystals by incorporating a gelable colloid. A further emulsification step follows in an aqueous colloidal solution that forms a gel capable of producing a dry powder after a spray drying process. The product obtained is a microcrystalline dispersion in edible oil used to impart color to margarine, fruits and vegetables in which the βcarotene occurs in the form of microdispersion in a protective hydrophilic colloid. -
US Patent 3,523,138 issued to Grant describes the improved bioavailability of carotenoids in poultry, after a saponification reaction has taken place in order to free the xanthophylls from the long chain fatty acid esters. -
US Patent 3,535,426 issued to Hawks discloses that a saponified mixture of xanthophylls become more stable, and consequently more bioavailable, when admixed with a fat and ethoxyquinolein. -
Cathrein describes in US Patent 5,364,563 a process for producing powdered carotenoid preparations by obtaining a suspension in oil that is brought in contact with superheated steam, producing an emulsion that is spray dried. -
Eugster et al, in US Patents 5,496,813 and5,536,504 obtain ultra microemulsions that form spontaneously dispersible concentrates containing xanthophylls esters that have anti tumor activity. -
Gellenbeck in US Patent 5,827,539 obtains a finely ground mixture of carotenoids with an oil and a spray dried encapsulated form that is water dispersible. -
Luddecke, et al, in US Patent 5,863,953 describes the obtention of an oil dispersion of carotenoids, which is used to prepare a double dispersion system with particles sizes of 100 microns, stabilized by a protective colloid and emulsifiers. -
Sanders and Herink published in WO9947001 -
Kolter et al, describe in US Patent 5,891,907 stable aqueous solubilizates of carotenoids and vitamins, in which the carotenoids and the water insoluble vitamins with the aid of a nonionic emulsifier, yield a micelle, which particles are smaller than 100 nm. -
Luddecke et al, describe in US Patent 5,895,659 the preparation of finely dispersed carotenoids or retinoid suspensions by dissolving the carotenoid or retinoid in a volatile, water-miscible organic solvent, under elevated pressures, and immediately after 10 seconds, mix the solution with an aqueous medium containing an emulsifier. -
Schweikert et al in US Patent 5,925,684 describe a stable oil in water emulsion consisting of an aqueous phase and an oil phase which is very finely dispersed by means of an emulsifier, and wherein the carotenoid is present in the oil phase in a concentration above the saturation solubility of the carotenoid in the oil at room temperature. -
Auweter et al, describe in US Patent 5,968,251 the preparation of coldwater dispersible powders by preparing a molecular-disperse solution of a carotenoid, with or without an emulsifier and/or edible oil, in a volatile, water-miscible organic solvent at elevated temperature and adding an aqueous solution of a protective colloid; whereupon the hydrophilic solvent is transferred into the aqueous phase, and the hydrophobic phase of the carotenoid results as a nanodisperse phase, removing the solvent by heating the hydrosol and converting it in a water dispersible dry powder. -
Gellenbeck in US Patent 5,976,575 describes the grinding of a mixture of carotenoids and oil to reduce the carotenoids particle size, emulsifying the mixture with an encapsulating mixture and drying the emulsion. -
Handelman in US Patent 6,075,058 describes the composition of lutein and zeaxanthin along with cholesterol, olive oil, egg yolk phospholipids, alpha tocopherol and aqueous sodium chloride. The mixture is prepared by mixing the lipid ingredients into ethanol, evaporating the ethanol, and dispersing the lipids as an emulsion in the sodium chloride solution. -
Kowalski et al, describe in US Patent 6,093,348 a method for the manufacture of carotenoid powders, weherein an aqueous suspension of the carotenoid is heated to melt the carotenoid in the presence of a surfactant and a protective colloid under high temperatures and high pressures (HTHP process). The suspension is then homogenized under high pressure to form an emulsion. And the resulting emulsion is dried to obtain the carotenoid powder. -
Schliapalius in US Patent 6,132,790 describes a composition of a carotenoid in oil, a dispersion of a water dispersible matrix and a stabilizer, and a non-oil solvent and an emulsifier, all of natural sources. -
Koguchi, et al describe in US Patent 6,261,622 a method to provide a water-dispersible carotenoid preparation which can be added to various aqueous compositions with retaining dispersion stability even at low temperature, by dispersing pulverized carotenoids crystals with soybean extract fibers as emulsion stabilizer. -
Bewert et al, in US Patent 6,328,995 describe a procedure to stabilize dry powders which are insoluble in hot water and which contain one or more lipid soluble vitamins or carotenoids, formed in an aqueous dispersion containing a protein, a sugar and potassium and/or sodium phosphates. -
Stein et al, describe in US Patent 6,406,735 a process for the preparation of a pulverous composition of a finely divided carotenoid or retinoid comprising; forming a suspension of the active ingredient in a water-immiscible organic solvent containing an antioxidant and/or an oil, feeding the suspension through a heat exchanger and heating the suspension to a high temperature for a 5 seconds residence time, rapidly mixing the solution with an aqueous swellable colloid and further removing the organic solvent to obtain the pulverous preparation, all steps processed in a continuous sequence. -
Guerra-Santos, et al describe in US Patent 6,936,279 the obtention of microcrystalline form of carotenoids, particularly zeaxanthin, in an oily carrier. The "coarse-grained" carotenoids is dissolved in a suitable solvent as tetrahydrofuran, and mixed with a vegetable oil and an emulsifier. The mixture is injected along with an inert gas into a vacuum chamber in order to remove the solvent in a flash manner, not allowing the carotenoids crystals to grow. They obtain a microcrystalline suspension in the oil carrier. -
US-5,959,138 discloses a process to obtain a product having a high content of zeaxanthin, lutein or mixtures thereof, as short chain organic acid diesters of zeaxanthin, lutein or mixtures thereof, that can be used mainly for the pigmentation of broilers and egg yolks, as well as an intermediate in the cantaxanthin (β,β-Carotene-4,4'-dione) and astaxanthin (3,3'-Dihydroxy-β,β-carotene,4,4'-dione) synthesis, by reacting extracts obtained from marigold (Tagetes Erecta L.), or plant extracts that contain lutein, zeaxanthin or mixtures thereof in any proportion, with acetic or propionic anhydride under controlled conditions of temperature and pressure. The products obtained inUS-5,959,138 may be used in the present process. - Therefore to our knowledge, the novelty that is being disclosed in this patent has no previous precedings. Furthermore, none of the above described patents completely avoids the formation of carotenoids crystals, which as previously described, affect the absorption and bioavailability of carotenoids.
- By the process of the present invention, it is possible to obtain microemulsions or nanoemulsions of lutein, 3'epilutein, and zeaxanthin diacetates and dipropionates, as well as short chain diesters of capsanthin, capsorubin, astaxantin and the acetate and propionate of cryptoxanthin that readily form micelles that are absorbed in the gut and diffuse through the mucous intestine wall.
- Crystalline solids are composed of atoms, ions, or molecules in a highly ordered geometric pattern (the crystal lattice). The atoms, ions or molecules are held in their positions by electrostatic, dipole and/or London forces. When a pure crystalline solid is heated, the atoms, ions or molecules vibrate more and more rapidly until at a definite temperature the thermal motion of the particles becomes great enough to overcome the forces of attraction. Then the atoms, ions or molecules enter a more random and mobile state, the liquid state. The melting point of a solid is defined as the temperature at which the liquid and solid phases are in equilibrium. A pure solid will generally melt sharply because the forces of attraction between the particles are the same. However, the presence of a foreign particle in a crystal lattice interrupts its uniform structure and the forces of attraction are weakened. An "impure" compound melts at a lower temperature and over a wider range. Thus, in the process of the present invention, the melting point of carotenoid derivatives is lowered (depressed) by the addition of a soluble material to the solution.
- It is a common practice in the pigment industry to carry on a saponification reaction, or hydrolysis, of the fatty acids diesters of lutein and zeaxanthin as they naturally occur in the oleoresin of Tagetes erecta, in order to free the above mentioned carotenoids. It is also a common practice to hydrolyze the oleoresin of Capsicum annum to free the capsanthin and capsorubin from the fatty acids, as they occur in the natural form.
- Such hydrolysis is carried out either in an aqueous media by means of a strong alkali and suitable emulsifiers and temperature, or in a non polar organic media like propylene glycol, also under the action of a strong alkali and temperature. In both cases, as the xanthophylls are free they become insoluble in the reaction media and occur in crystalline form.
- The reaction mass can be used to prepare pigment premixes or water dispersions, but the physical structure of the carotenoids is always microscopic crystals.
- In the different purification and refinement processes aimed to obtain carotenoids of high purity, the saponified oleoresin mass is subject to several stages of selective organic polar, or non polar solvent extractions, or supercritical CO2 extractions, and recrystallizations in order to isolate the carotenoids from the other components of the mass. At the end of such purification processes, the carotenoids, as expected, occur in crystalline form.
- In the process of the present invention the micelles, microemulsions and nanoemulsions of oxycarotenoids derivatives, are obtained during the reaction of such oxycarotenoids with short chain organic acids like acetic or propionic acid. Such microscopic emulsions occur during the course of such reaction under controlled conditions and further processing. The carotenoids derivatives obtained by this process do have melting points that are lower as compared to the melting points of the free carotenoids. Surprisingly the carotenoid derivatives crystals under certain conditions of temperature, time, and in the presence of lipids, emulsifiers, and moisture, form stable micelles occluded in the lipid matrix and remain as such at normal conditions of temperature and pressure. Such lipid carotenoid micelles contain melt down oxycarotenoids derivatives, and are non-crystalline.
- It is therefore a main object of the present invention, to provide a process for obtaining a microscopic physical state of xanthophylls or oxycarotenoids derivatives forms such as diacetates or dipropionates derivatives, which are readily incorporated in the digestive system as micelles providing an improved bioavailability, as compared to the bioavailability of carotenoids that are ingested in diverse preparations that contain microscopic carotenoids crystals.
- The patent also discloses a process for the preparation of microemulsions and micelles and its uses in administering lutein and zeaxanthin diacetates or dipropionates, and those of other oxycarotenoids derivatives to humans, as well as for the pigmentation of broilers, egg yolks, and marine species as salmonids, crustaceans and fish.
- These and other objects and advantages of the present invention will become apparent to those persons having an ordinary skill in the art, from the following detailed description of the embodiments of the invention.
- The process of the present invention will now be described making reference to a preferred embodiment thereof and to specific examples of use and application of the product, wherein the process of the present invention comprising:
- a) Incorporating the oxycarotenoids derivatives comprising diacetates and dipropionates, obtained from: lutein, 3'epilutein, zeaxanthin, mesozeaxanthin, capsanthin, astaxanthin, and cryptoxanthin monoacetate and cryptoxanthin monopropionate, or their mixtures with the components of a vegetable matrix or components of similar nature, comprising fatty acids, phospholipids, emulsifiers and/or sterols inside a reactor;
- b) Raising the temperature of the reactor to a temperature of between about 60 to 70o C under a nitrogen atmosphere;
- c) Adding a surfactant, or mix of surfactants, in an amount of 5 to 50% by weight to the reactor mix, such as Tween 80, comprising polyoxyethylene sorbitan, particularly polysorbate 20-85 such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 70, polysorbate 80(Tween 80), polysorbate 81, polysorbate 85; polyoxyethylene stearates (polyoxyethylene(40) stearate), polyoxyethylene(8) stearate and polyoxyethylene (40) stearate; polyoxyethylene oleates; polyoxyethylene laurates;. polyoxyethylene castor oil derivatives; sorbitan esters; polyoxyethylene sorbitan fatty acid esters; poloxamers such as Pluronic F-65LF™; Pluronic L-62LF™ and Pluronic L62D™ (BASF Wyandotte Corp.) or tyloxapol, polyoxyethylene fatty acid esters such as EMULPHOR™ (GAF Corp).
- d) Stirrring the mix obtained in step c) during a period of two hours;
- e) Adding to the mix obtained in step d) a phospholipid in an amount of 5 to 50% by weight, said phospholipids selected from the group comprising: lecithins; Epikuron 120™ (Lucas Meyer, which is a mixture of about 70% phosphatidylcholine and 12% phosphatidylethanolamine and about 15% other phospholipids); Ovothin 160™ or Ovothin 200™ (Lucas Meyer, phosphatidylcholine, 18% phosphatidylethanolamine and 12% other phospholipids); or a purified phospholipid mixture, such as that obtained from egg yolk, or Lipoid E-80™ (Lipoid AG, which is a phospholipid mixture comprising about 50% phosphatidylcholine, 5% phosphatidylethanolamine, 3.6% non-polar lipids and about 2% sphingomyeline);
- f) Stirring the mix obtained in step e) during a period of time of one hour in order to homogenize the mix,
- g) Adding to the mixture obtained in step f) water in an amount of 1 to 40 % by weight;
- h) Raising the temperature of the mix obtained in step g) at a temperature of between about 90 to 110o C while maintaining the pH of the lipid matrix at from 5.5 to 8.5, preferably at a pH of from 6.5 to 7.0 and submit the mix to a refluxing cycle during a time period of between about 2 to 10 hours until it is observed under a 100X microscope that the carotenoids derivatives crystals melt down in the lipid non polar matrix, thus producing oxycarotenoids derivatives microemulsions in a ratio of 0.001% to 40% by weight wherein the microemulsions comprises an internal homogeneous dispersed lipophilic phase of melted oxycarotenoids derivatives, and an external hydrophilic phase mainly formed by vegetable lipids and emulsifiers. The order of steps g) and h) may be inverted.
- The microemulsions obtained can be reduced in size to obtain nanoemulsions by intense high speed and high shear mechanical agitators for a period of 3 to 4 hours, or by emulsifying machines operating at pressures of the order of 3,000 to 4,000 psi.
- The microemulsions obtained in step h) may be dispersed in an aqueous or lipid media, suitable to be incorporated in human supplements or foods, or feeds for pets, poultry or aquatic animals at a temperature of between about 40 to 70o C in order to, among other applications: noticeably improving the absorption and bioavailability of xanthophylls diacetates and dipropionates obtained from lutein, zeaxanthin, capsanthin and capsorubin, for the purpose of pigmentation of broilers skin and egg yolks or improving the bioavailability of the carotenoids derivatives obtained from: lutein, zeaxanthin, capsanthin, capsorubin, and astaxanthin when incorporated in the feed of marine organisms such as shrimp and crustaceans, salmon, trout, red sea bream, yellow tail tuna.
- The aqueous or lipid media microemulsions dispersion may comprise: water containing carotenoids derivatives obtained from the following carotenoids: lutein, 3'epilutein, zeaxanthin, isozeaxanthin, mesozeaxanthin, capsanthin, capsorubin, astaxanthin and cryptoxanthin, which can be administered to humans as a supplement to prevent the degeneration of human tissues due to the presence of free radicals; or oil, preferebly fish oil with a high content of omega 3 fatty acids, containing carotenoids derivatives which noticeably improves the bioavailability of oxycarotenoid derivatives like lutein, 3'epilutein, zeaxanthin, meso zeaxanthin, iso zeaxanthin, capsanthin, capsorubin and astaxanthin diacetates or dipropionates in humans which can be administered to humans as a supplement to prevent and protect cells and tissues from the damaging effects of free radicals and singlet oxygen, to improve the hearth and cardiovascular conditions, and at the same time to help reduce the risk of macular degeneration and the formation of cataracts.
- The microemulsion of carotenoids derivatives obtained from: lutein, 3'epilutein, zeaxanthin, iso zeaxanthin, meso zeaxanthin, capsanthin, capsorubin, and astaxanthin obtained in step h) may also be encapsulated by suitable maltodextrins; sugars; animal, vegetable or fish gelatins in order to prepare beadlets for supplementing the nutrition of humans.
- The above described process helps the dissolution of crystals and avoids the oxycarotenoids derivatives contained in the original matrix to recrystallize at room temperature.
- Most of the carotenoids are unstable and tend to degrade when exposed to light, oxygen and organic or inorganic acids at elevated temperatures. While processing carotenoids under such conditions all operations should be performed either under vacuum or under an inert atmosphere such as a nitrogen atmosphere. It was observed a remarkable stability of the short chain diester oxycarotenoids, namely diacetates or dipropionates, after being subject to such conditions.
- Since the diacetate and the dipropionates are derivatives of carotenoids of non polar nature, they tend to melt down and remain as micro or nanospheres dispersed in the lipid matrix at a lower temperature than the melting point of the pure carotenoids. The presence of lipids, free fatty acids, waxes and sterols, as occur in the natural oleoresin, called lipid matrix, also help to reduce the melting point of the oxycarotenoids derivatives.
- It was found that after the hydrolysis of xanthophylls fatty acid esters is completed, and the excess alkali has been neutralized by means of a diluted acid like phosphoric acid, acetic acid, hydrochloric acid, perchloric acid, or mixtures thereof, and brought about to a pH from 5-9, preferably a pH of 5.5-6.5, a two phase system is formed. The organic phase that contains the carotenoids crystals is rinsed several times with warm water to remove any acid and salts traces. The supernatant or lipid mass mainly consists of free fatty acids, and minor compounds like waxes, phospholipids and sterols, that occur naturally with the carotenoids esters. When this lipid mass is dried under vacuum and the carotenoids are esterified according to
US Patent No. 5,959,138 with acetic anhydride or propionic anhydride, a supernatant organic phase is obtained where the carotenoids short chain diesters crystals are embedded. The compounds present in the organic matrix "impurities" interact by remarkably decreasing the carotenoids short chain diesters' melting point, and help to improve the stability of the oxycarotenoids derivatives during the heating process. The main fatty acids are myristic, palmitic and stearic as naturally occur in the Tagetes erecta extract; and oleic, linoleic and linolenic acids are found in the Capsicum annum extracts. - By increasing the temperature to 90-110 °C under agitation and under an inert atmosphere, the carotenoids derivatives crystals are melted down in the lipid non polar matrix producing a homogeneous phase. Although the melting points of pure carotenoids crystals are high; we observed that the original composition of the matrix and the incorporation of moisture, vegetable oil, additional fatty acids and emulsifiers, as well as a suitable control of the pH media during the melting process, they interact with the carotenoids crystals provoking in situ a sensible decrease of the melting point of the oxycarotenoids derivatives, producing a dispersion of non-crystalline nanoparticles of carotenoids in micellar form with average particle sizes of 2-5 nanometers. The present process generates oxycarotenoid derivatives that interact with the components of the matrix and at the given conditions of temperature, time and agitation, produce carotenoids compounds in a non-crystalline state that upon their incorporation in micelles notably improve their absorption and bioavailability.
- The micelles obtained can be diluted with more lipid material. Such lipid material may comprise one or more members selected from the group consisting of vegetable oil, mineral oil, medium chain tryglicerides (MCT) oil (i.e. a triglyceride oil in which the carbohydrate chain has about 8-12 carbon atoms), oily fatty acids, isopropyl myristate, oily fatty alcohols, esters of sorbitol and fatty acids, oily sucrose esters or mixtures thereof. Examples of phospholipids which may be used in the emulsions of the invention are soy lecithins, lecithins; Epikuron 120™ which is a mixture of about 70% phosphatidylcholine and 12% phosphatidylethanolamine and about 15% other phospholipids; Ovothin 160™ or Ovothin 200™. Phosphatidylcholine, 18% phosphatidylethanolamine and 12% other phospholipids; a purified phospholipid mixture, e.g. such which is obtained from egg yolk; Lipoid E-80™ (Lipoid AG, Ludwigshafen); fatty acids as myristic, palmitic, stearic as naturally occur in the Tagetes erecta extract; and oleic, linoleic and linolenic acids emulsifiers like Polyoxyethylene sorbitan particularly polysorbate 20-85 such as polysorbate 20, polysorbate 40 polysorbate 60, polysorbate 65, polysorbate 70, polysorbate 80 (Tween 80™), polysorbate 81, polysorbate 85, polyoxyethylene (8) stearate and polyoxyethylene (40), etc. in order to elaborate different preparations or formulations.
- An impure solid compound melts at a lower temperature and over a wider range. Thus a solid's compound's melting point may be lowered (depressed) by the addition of a soluble material to the solution.
- The melting points (mp) of pure carotenoids, as well as the melting points of some of their derivatives are as follows (The Merck Index, Twelfth Edition, 1996):
Lutein mp 190o C Lutein Diacetate mp 170o C Lutein Dipropionate mp 138o C Lutein Dipalmitate mp 92o C Zeaxanthin mp 215o C Zeaxanthin Diacetate mp 155o C Zeaxanthin Dipropionate mp 142o C Zeaxanthin Dipalmitate mp 97o C Astaxanthin mp 216o C Astaxanthin Diacetate mp 205o C Capsanthin mp 182o C Capsanthin Diacetate mp 150o C Capsanthin Dipalmitate mp 95o C Crptoxanthin mp 159o C Cryptoxanthin Monoacetate mp 117o C - It can be observed that the melting points of the pure carotenoids are higher in regard to the melting points of their corresponding derivatives. Therefore in the process to obtain carotenoids derivatives from pure carotenoids, the melting point of oxycarotenoids is reduced from 50 to 116° C with respect to the melting point of the pure carotenoid, when the diacetate derivatives are incorporated in the process; and the melting point of oxycarotenoids is reduced from 30 to 50° C with respect to the melting point of the pure carotenoid, when propionate derivatives are incorporated in the process. As the molecular weight of the carotenoid derivative is larger, then the melting point of such derivative is further reduced, as compared to the melting point of the pure carotenoid. Substances as Tween 80 and/or lecithin or its different compounds, that can be considered as "impurities" (not contaminants) may provoke a sensible reduction of the pure carotenoids melting points. It is important to notice that when the carotenoids derivatives are melt down at such low temperatures, no degradation compounds are obtained in the process.
- The obtained micelles can be easily dispersed in water, forming stable microemulsions or nanoemulsions, composed of an internal homogeneous lipophilic phase of carotenoids derivatives that do not contain any crystals, and an external hydrophylic phase formed by lipids and emulsifiers. It is a true oxycarotenoid derivatives solute contained in the micelles. Due to its soft nature such lipid carotenoid derivatives can be easily micronized by means of a homogenizing machine into a microemulsion or a nanoemulsion. Crystalline structures per se are hard to break by mechanical means and therefore are very difficult to be worked into microemulsions and almost impossible to produce nanoemulsions in a non polar media.
- Surprisingly when the lipid oxycarotenoid derivatives microemulsions are incorporated in the feed of laying hens or broilers, the pigmentation efficiency is noticeably improved as compared to the pigmentation obtained by premixes or water dispersions that contain the oxycarotenoids in crystalline form.
- It is a novelty also to obtain an improved absorption by humans of the oxycarotenoids derivatives as micromicelles in a lipid matrix of free fatty acids, phospholipids, sterols, waxes and different kinds of vegetable or fish oils and emulsifiers; as compared to the absorption of free carotenoids crystals dispersed in oil, regardless of the size of the crystals.
- The following examples illustrate the improved absorption and bioavailability of the microemulsions and nanoemulsions obtained from the lipid carotenoid derivatives dispersion. These examples are presented for illustrative purposes only and for a better understanding of the invention. However, they are not intended to limit the scope of the present invention.
- The oxycarotenoids derivatives described in the process of the present invention may be obtained by the following process:
- To five (5) kgs of aqueous saponified marigold oleoresin with a pH of 13, a 30 % diluted acetic acid is added with stirring until a pH of 7.0 is obtained. A separation of phases is observed and the aqueous phase is discarded. The organic phase is rinsed several times with 10 kg of lukewarm water to remove acid traces and polar compounds. The water is discarded and the temperature is raised to 90°C and a vacuum of 3mm Hg is applied under agitation. Once all the moisture has been removed from the mass, an amount of acetic anhydride is added slowly according to the process described in
US Patent No. 5,959,138 . - After the oxycarotenoids diacetate has been formed, the lipid matrix is incorporated in a suitable reactor under agitation, an amount of 1 kg of a vegetable oil or fish oil, fatty acid and an emulsifier mixture is added. The vessel is kept under a nitrogen atmosphere and the temperature is risen to 60-70°C
- An amount of 500 gr of Tween 80 is added and agitated for a period of 120 minutes.
- Afterwards an amount of 500 gr of lecithin is added and the mix is stirred for a period of 60 minutes.
- The temperature of the reactor is increased to 100° C until all of the lutein diacetate crystals disappear, as can be observed under a 100X microscope objective.
- The mass is immediately cooled down to room temperature and 2 kgs of water are added under agitation to obtain a colloidal suspension. The above procedure is carried in a closed vessel in the absence of light and under an atmosphere of nitrogen. This procedure helps the dissolution of crystals and avoids the oxycarotenoids derivatives contained in the original matrix to recrystallize at room temperature. The colloid solution is ready to be dispersed in solid carriers or emulsified in water to the desired concentration.
- The oxycarotenoids derivatives described in the process of the present invention may be obtained by the following process:
- To one kg of aqueous saponified red pepper oleoresin with a pH of 13, a 20 % aqueous phosphoric acid solution is added until a pH of 7.0 is reached upon stirring. A two phase separation is obtained, and the water phase is discarded. The organic phase is rinsed twice with two portions of 10 kgs of lukewarm water to remove acid traces and salts. The organic phase in the closed vessel is subject to a vacuum of 3 mm Hg until all the moisture has been removed. The capsanthin and capsorubin are then converted into diacetates according to the process described in
US Patent No.5, 959,138 . - After the oxycarotenoids diacetate has been formed, the lipid matrix is incorporated in a suitable reactor under agitation, an amount of 500 gr of oleic acid.
- The vessel is kept under a nitrogen atmosphere and the temperature is risen to 60-70°C .
- An amount of 100 gr of polysorbate 60 is added and agitated for a period of 120 minutes.
- Afterwards an amount of 200 gr of lecithin is added and the mix is stirred for a period of 60 minutes.
- The temperature of the reactor is increased to 95° C until all of the carotenoids diacetate crystals disappear, as can be observed under a 100X microscope objective.
- The mass is immediately cooled down to room temperature and 2 kgs of water are added under agitation to obtain a colloidal suspension. The above procedure is carried in a closed vessel in the absence of light and under an atmosphere of nitrogen. This procedure helps the dissolution of crystals and avoids the oxycarotenoids derivatives contained in the original matrix to recrystallize at room temperature. The colloid solution is ready to be dispersed in solid carriers or emulsified in water to the desired concentration.
- The oxycarotenoids derivatives described in the process of the present invention may be obtained by the following process:
- 100 grams of purified free lutein concentrate (85% by weight, AOAC) are blended with 150 grams of food grade oleic acid and 5 grams of α-tocopherol, and the mass is agitated under vacuum for a time of 120 minutes at 90° C to remove any traces of moisture. Then an amount of acetic anhydride is added according to the process described in
US Patent No. 5,959,138 until all of the lutein has been converted into the diacetate. - The mass is rinsed several times with lukewarm water several times to remove any acid traces and salts.
- The vessel is kept under a nitrogen atmosphere and the temperature is risen to 60-70°C .
- An amount of 20 gr of Tween 80 is added and agitated for a period of 120 minutes.
- Afterwards an amount of 40 gr of lecithin is added and the mix is stirred for a period of 60 minutes.
- The temperature is raised to 100°C under an atmosphere of nitrogen for a period of 180 minutes until no carotenoids crystals are observed under a 100X microscope objective.
- Once the lutein diacetate crystals have melt down, the mass is cooled below 40 °C, 50 grams of water are added and a colloid suspension is obtained in a high speed agitator. The colloidal suspension can be dispersed in solid carriers, vegetable oils or diluted in water.
- Two identical groups (Group A and Group B) of three weeks old broilers were placed in suitable pens, containing 50 chicken each. They were fed identical feeds (ad-libitum) containing different pigmenting concentrates. Group A broilers feed contained 80 ppm of a blend of micellar lutein diacetate and micellar zeaxanthin diacetate prepared according to example 1. Group B broilers feed contained 90 ppm of a standard lutein pigment (saponified and dispersed in water) plus 3 grams of cantaxanthin.
- After four weeks the broilers were slaugthered, processed and refrigerated. The average deposition of pigment in the broilers shank (palmar tissue) was almost identical: 14.9 ppm of total xanthophylls for Group A; and 15.0 ppm of total xanthophylls for Group B.
- A Minolta Chromameter was used to determine the pigment reading in the breast skin of each refrigerated broiler. The average readings obtained for each group are as follows:
Group Yellowness (b*) Redness (a*) Luminosity A 27.12 -1.19 76.12 B 26.21 0.90 74.09 - The above data show that for a common person no difference can be appreciated by the naked eye among the pigmentation of the two groups.
However, such information reveals that broilers from Group A, whose feed contained only 80 ppm of micellar lutein diacetate and micellar zeaxanthin diacetate, absorbed much more efficiently the pigment than those from Group B whose feed contained 90 ppm of standard lutein pigment water dispersion plus 3 ppm of red cantaxanthin. - 10 healthy non smoking students (range 22-27 years), were subject to the following two treatments:
- (A) 4 weeks of ingesting one gelatin capsule at noon meal, containing 20 mg of crystalline lutein dispersed in soybean oil and after a 12 hours fast (overnight) blood samples were taken early morning next day for plasma analysis.
- (B) After a 2 weeks washout period interval, the same group of subjects were given during a period of 4 weeks a gelatin capsule containing a micellar dispersion of lutein diacetate (prepared as described in example 3) in soybean oil. Each capsule contained 24.2 mg of lutein diacetate and was ingested at lunch time. After 12 hours fast, blood samples were collected early morning next day for plasma analysis.
- The results obtained were as follow:
Table 1 One gel capsule per day containing 20 mg lutein in soybean oil Analysis of blood serum in nmol/dL Subject 7 days 14 days 21 days 28 days A 38.1 38.7 39.2 39.8 B 23.4 24.8 26.4 27.3 C 17.5 20.5 23.8 25.1 D 21.2 23.5 25.2 29.1 E 20.6 21.5 22.1 22.4 F 35.7 41.0 46.0 49.7 G 42.2 44.7 46.6 47.0 H 15.8 16.4 17.3 19.3 I 38.1 38.9 40.1 39.2 J 24.7 25.6 26.6 27.7 Average 27.7 29.6 31.3 32.6 Std. Dev. 9.8 10.1 10.6 10.6 Var. Coef. 0.4 0.3 0.3 0.3 Max 42.2 44.7 46.6 49.7 Min 15.8 16.4 17.3 19.3 Table 2: one gel capsule per day containing 24.2 mg of lutein diacetate in soybean oil Analysis of blood serum in nmols/dL Subject 7 days 14 days 21 day 28 days A 76.3 88.3 99.3 118.7 B 46.3 51.6 57.1 68.1 C 31.5 39.3 49.3 65.2 D 39.4 51.2 63.0 84.1 E 40.2 46.2 52.5 62.6 F 66.7 87.1 106.8 146.8 G 82.3 98.9 113.0 134.0 H 23.6 29.4 35.6 48.2 I 71.3 81.8 94.6 115.8 J 46.6 51.9 60.3 74.1 Average 52.4 62.6 73.1 91.8 Std. Dev. 20.2 24.1 27.5 34.2 Var. Coef. 0.4 0.4 0.4 0.4 Max 82.3 98.9 113.0 146.8 Min 23.6 29.4 35.6 48.2 - The improvement in the absorption and bioavailability can be determined by the ratio of the average absorption of the lutein diacetate (Table 2), divided by the average absorption of the free lutein (Table 1): 91.8/ 32.6 = 2.81 times
Claims (15)
- A process for obtaining stable microemulsions that are composed of a solubilizate of derivatives of oxycarotenoids of short chain organic acids, selected from the group consisting of diacetates and dipropionates of lutein, 3'epilutein, zeaxanthin, iso zeaxanthin, meso zeaxanthin, capsanthin, capsorubin, astaxanthin, and cryptoxanthin monoacetate and monopropionate, which are melted down from the naturally occurring original lipid vegetable matrix in the presence of lipids, phospholipids, fatty acids, emulsifiers and moisture which are better absorbed and more bioavailable, as compared with oxycarotenoids in crystalline form, which process comprises the steps of:a) adding diacetate and dipropionate derivatives of oxycarotenoids with sterols, fatty acids, lipids, phospholipids, emulsifiers, or mixtures thereof, derived from a vegetable matrix in a reactor;b) raising the temperature of the reactor to about 60 to about 70.degree. C.;c) adding a surfactant to obtain a mixture of derivatives of oxycarotenoids and a surfactant;d) stirring the mixture obtained in step c) for a period of time sufficient to homogenize the mixture;e) adding to the mixture obtained in step d) from about 5% to about 50%, by weight, of a phospholipid;f) stirring the mixture obtained in step e) for a period of time sufficient to homogenize the mix;
and eitherg) adding to the mixture obtained in step f) about 1% to about 40%, by weight, of water; andh) raising the temperature of the mixture obtained in stepg) to about 90 to about 110⌀ C. while maintaining the pH at from about 5.5 to about 8.5 and refluxing the mixture for a period of time sufficient to melt the crystals of the oxycarotenoids derivatives in the non polar lipid matrix
org') raising the temperature of the mixture obtained in step f) to about 90 to about 110.degree. C. while maintaining the pH at from about 5.5 to about 8.5 and refluxing the mixture for a period of time sufficient to melt the crystals of the oxycarotenoids derivatives in the non polar lipid matrix whereby microemulsions of the oxycarotenoids derivatives are formed; andh') adding to the mixture obtained in step g') about 1% to about 40%, by weight, of water.
whereby microemulsions of the oxycarotenoids derivatives are formed. - The process as claimed in claim 1, wherein the surfactant comprises from about 5 to 50%, by weight, of a surfactant selected from the group consisting of polyoxyethylene sorbitan, polyoxyethylene stearate, polyoxyethylene oleate polyoxyethylene laureates, sorbitan esters, poloxamers and tyloxapol, and polyoxyethylene fatty acid esters.
- The process as claimed in claim 1, wherein the phospholipid is selected from the group consisting of a zwitterionic surfactant; a surfactant consisting of about 70% phosphatidylcholine and 12% phosphatidylethanolamine and about 15% other phospholipids; of a surfactant consisting of phosphatidylcholine, 18% phosphatidylethanolamine and 12% other phospholipids; or a purified phospholipid mixture, such as that obtained from egg yolk, or a surfactant consisting of about 50% phosphatidylcholine, 5% phosphatidylethanolamine, 3.6% non-polar lipids and about 2% sphingomyeline.
- The process as claimed in claim 1, wherein in step g) the mixture comprises fatty acids selected from the group consisting of myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, sterols, methyl sterols, vegetable C.sub.40, C.sub.42, and C.sub.46 waxes, tocopherols, tocotrienols, phospholipids, and mixtures thereof.
- The process as claimed in claim 1, wherein in step h) the pH is maintained at about 6.5 to about 7.0.
- The process as claimed in claim 1, wherein step h) is carried out in a vacuum.
- The process as claimed in claim 1, wherein the microemulsions of derivatives of oxycarotenoids are further dispersed in an aqueous or lipid media suitable for incorporation in human supplements or foods, or feeds for pets, poultry or aquatic animals.
- The process as claimed in claim 1, wherein the microemulsions of derivatives of oxycarotenoids are further dispersed in an aqueous or lipid media at a temperature of between about 40 to about 70.degree. C.
- The process as claimed in claim 1, wherein the microemulsions of derivatives of oxycarotenoids are further dispersed in an aqueous or lipid media to improve the absorption and bioavailability of xanthophylls diacetates and dipropionates obtained from lutein, zeaxanthin, capsanthin and capsorubin for use in the pigmentation of the skin of broilers and egg yolks.
- The process as claimed in claim 1, wherein the microemulsions of derivatives of oxycarotenoids are further dispersed in an aqueous or lipid media to improve the absorption and bioavailability of the carotenoids derivatives obtained from lutein, zeaxanthin, capsanthin, capsorubin, and astaxanthin when incorporated in the feed of marine organisms.
- The process as claimed in claim 1, wherein the microemulsions of oxycarotenoids derivatives are further dispersed in lipids or water containing carotenoids derivatives obtained from lutein, 3'epilutein, zeaxanthin, isozeaxanthin, mesozeaxanthin, capsanthin, capsorubin, astaxanthin and cryptoxanthin, which can be administered to humans as a supplement to prevent and protect cells and tissues from the damaging effect of free radicals and singlet oxygen, as well as to prevent the risk of cancers and stroke.
- The process as claimed in claim 1, wherein the microemulsions of diacetates and dipropionates of oxycarotenoids of lutein, 3'epilutein, zeaxanthin, isozeaxanthin are further dispersed in fish oil with a high content of omega 3 fatty acids which aids in reducing the risk of macular degeneration and the formation of cataracts in humans when ingested.
- The process as claimed in claim 1, wherein the microemulsions contains oxycarotenoids derivatives of diacetates or dipropionates of lutein, 3'epilutein, zeaxanthin, Isozeaxanthin, and are further dispersed in fish oil with a high content of omega 3 fatty acids, whereby the cardiovascular health of humans is improved when ingested.
- The process as claimed in claim 1, wherein the melting point of the oxycarotenoids are reduced by about 50 to about 116.degree. C. with respect to the melting point of the pure carotenoid when the diacetate derivatives are incorporated in the process and the melting point of the oxycarotenoids is reduced by 30 to 50.degree. C. with respect to the melting point of the pure carotenoid when propionate derivatives are incorporated in the process.
- The process as claimed in claim 1, wherein the microemulsions obtained are further reduced in size to obtain nanoemulsions by the use of intense high speed and high shear mechanical agitators, or by emulsifying machines operating at pressures of the order of about 3,000 to about 4,000 psi.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/506,974 US7435846B2 (en) | 2006-08-18 | 2006-08-18 | Absorption and bioavailability of carotenoids, formulations and applications |
PCT/MX2007/000024 WO2008020747A1 (en) | 2006-08-18 | 2007-03-08 | A method for obtaining stable micro-emulsions of derivatives of oxycarotenoids of short-chain organic acids, micro-emulsions obtained, and formulation which contains these |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2062570A1 EP2062570A1 (en) | 2009-05-27 |
EP2062570A4 EP2062570A4 (en) | 2012-07-25 |
EP2062570B1 true EP2062570B1 (en) | 2014-01-15 |
Family
ID=39082241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07747170.4A Not-in-force EP2062570B1 (en) | 2006-08-18 | 2007-03-08 | A method for obtaining stable micro-emulsions of derivatives of oxycarotenoids of short-chain organic acids, micro-emulsions obtained, and formulation which contains these |
Country Status (4)
Country | Link |
---|---|
US (1) | US7435846B2 (en) |
EP (1) | EP2062570B1 (en) |
JP (1) | JP2010502575A (en) |
WO (1) | WO2008020747A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4868587B2 (en) * | 2006-09-26 | 2012-02-01 | ユニチカ株式会社 | Cryptoxanthin-containing composition |
US20090118228A1 (en) * | 2007-11-07 | 2009-05-07 | Bristol-Myers Squibb Company | Carotenoid-containing compositions and methods |
WO2009112506A1 (en) * | 2008-03-11 | 2009-09-17 | Dsm Ip Assets B.V. | Novel use of carotenoid (ester)s |
US20120157547A1 (en) * | 2010-12-21 | 2012-06-21 | Ricardo Montoya-Olvera | Compositions and applications of carotenoids of improved absorption and bioavailability |
US8754126B2 (en) | 2010-12-29 | 2014-06-17 | Abbott Laboratories | Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child |
AU2013363208B2 (en) * | 2012-12-19 | 2016-04-14 | ew nutrition Carotenoid Technologies S.A.U. | Xanthophyll compositions and methods of use |
SG11201507212TA (en) | 2013-03-13 | 2015-10-29 | Abbott Lab | A composition for enhancing newborn infant cognitive, brain and/or cns development and method of using same |
CN105188411A (en) * | 2013-03-13 | 2015-12-23 | 雅培制药有限公司 | Method of enhancing bioavailability of DHA and other lipid-soluble nutrients |
MY169122A (en) | 2013-03-13 | 2019-02-18 | Abbott Lab | Infant nutritional product with rrr alpha-tocopherol |
WO2015069974A1 (en) * | 2013-11-07 | 2015-05-14 | Abbott Laboratories | Capsules containing nutritional supplement formulations with enhanced absorption of lipophilic nutrients |
KR101699426B1 (en) * | 2013-12-11 | 2017-01-24 | 헬스-에버 바이오테크 컴퍼니 리미티드 | Pharmaceutical compositions of carotenoid |
US9622970B2 (en) * | 2014-05-08 | 2017-04-18 | Yaguang Liu | Pharmaceutical composition containing lutein and antioxidant for treating and preventing human disease |
US9968565B2 (en) | 2015-03-02 | 2018-05-15 | Omniactive Health Technologies Limited | Method for protection and improvement of liver health with meso-zeaxanthin compositions |
CN104664168B (en) * | 2015-03-16 | 2018-02-16 | 广州益牲宝动物药业有限公司 | A kind of piglet specific complex vitamin microemulsion preparation and its preparation method and application |
IT201700045343A1 (en) * | 2017-04-26 | 2018-10-26 | Micro Sphere Sa | PROCESS FOR THE PREPARATION OF A FOOD AND SUPPLEMENTARY SUPPLEMENTER SO OBTAINED |
EP3424494A1 (en) * | 2017-07-07 | 2019-01-09 | SolMic Research GmbH | Stable cannabinoid compositions |
GB201801986D0 (en) * | 2018-02-07 | 2018-03-28 | Ip Science Ltd | Anthocyanins and used thereof |
JP2024530364A (en) * | 2021-07-01 | 2024-08-19 | ケミン、インダストリーズ、インコーポレーテッド | Microemulsion bases for improved dye absorption and related methods |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2861891A (en) * | 1956-12-13 | 1958-11-25 | Hoffmann La Roche | Water dispersible carotenoid compositions and process of making the same |
US3523138A (en) * | 1965-03-01 | 1970-08-04 | Eastman Kodak Co | Treatment of marigold petal meal to obtain a xanthophyll product |
US3535426A (en) * | 1966-07-08 | 1970-10-20 | Eastman Kodak Co | Stabilization of xanthophylls |
ATE96312T1 (en) * | 1989-07-25 | 1993-11-15 | Hoffmann La Roche | PROCESS FOR THE MANUFACTURE OF CAROTINOID PREPARATIONS. |
CH681153A5 (en) * | 1991-01-28 | 1993-01-29 | Marigen S.A. | New and sterolester- sterolphosphorverbindungen. |
JPH0538273A (en) * | 1991-08-06 | 1993-02-19 | Saneigen F F I Kk | Extracted carotene preparation |
US6132790A (en) * | 1991-09-06 | 2000-10-17 | Betatene Limited | Carotenoid composition |
DE19609538A1 (en) * | 1996-03-11 | 1997-09-18 | Basf Ag | Finely divided carotenoid and retinoid suspensions and process for their preparation |
CH685189A5 (en) * | 1993-11-19 | 1995-04-28 | Marigen Sa | Ultramicroemulsions spontaneously dispersible concentrates with antitumoral effective xanthophyll esters. |
JPH09157159A (en) * | 1995-12-11 | 1997-06-17 | Lion Corp | Composition containing carotinoid |
US5827539A (en) * | 1995-12-28 | 1998-10-27 | Amway Corporation | Dry carotenoid-oil powder and process for making same |
DE19609476A1 (en) * | 1996-03-11 | 1997-09-18 | Basf Ag | Stable parenteral administration suitable carotenoid emulsions |
DE19609477A1 (en) * | 1996-03-11 | 1997-09-18 | Basf Ag | Stable aqueous solubilisates of carotenoids and vitamins |
DE69728206T2 (en) * | 1996-05-14 | 2005-03-10 | Dsm Ip Assets B.V. | Production process for carotenoid compositions |
DE19637517A1 (en) * | 1996-09-13 | 1998-03-19 | Basf Ag | Production of powdered, cold water dispersible carotenoid preparations and the use of the new carotenoid preparations |
TW371619B (en) * | 1996-10-07 | 1999-10-11 | Dsm Ip Assets Bv | Vitamin preparations for beverage applications |
DE19649062A1 (en) * | 1996-11-27 | 1998-05-28 | Basf Ag | Liquid, oil-miscible carotenoid preparations |
JPH1160980A (en) * | 1997-08-13 | 1999-03-05 | Kagome Co Ltd | Water-dispersible carotenoid pigment preparation |
GB9718636D0 (en) * | 1997-09-04 | 1997-11-05 | Smithkline Beecham Plc | Novel composition and use |
US5959138A (en) * | 1997-11-25 | 1999-09-28 | Industrial Organica S.A. De C.V. | Short chain diesters and process for making the same |
CA2261456A1 (en) * | 1998-02-23 | 1999-08-23 | F. Hoffmann-La Roche Ag | Preparation of a finely divided pulverous carotenoid preparation |
WO1999047001A1 (en) | 1998-03-18 | 1999-09-23 | Kemin Industries, Inc. | Increased bioavailability of lutein and zeaxanthin in humans and poultry using lysolecithin and lecithin |
US6075058A (en) * | 1998-12-12 | 2000-06-13 | Tufts University | Compositions for increased bioavailability of carotenoids |
US6328995B1 (en) * | 1999-09-24 | 2001-12-11 | Basf Aktiengesellschaft | Stable vitamin and/or carotenoid products in powder form and process for their production |
JP3803260B2 (en) * | 2001-03-23 | 2006-08-02 | 伯東株式会社 | Skin external preparation for whitening |
JP4859006B2 (en) * | 2001-05-25 | 2012-01-18 | 富士化学工業株式会社 | Stable astaxanthin-cyclodextrin inclusion compound and method for producing the same, and liquid, food and drink, feed, pharmaceuticals and cosmetics containing the inclusion compound |
ES2607487T3 (en) * | 2001-06-14 | 2017-03-31 | San-Ei Gen F.F.I., Inc. | Carotenoid color emulsion preparation |
US6635293B2 (en) * | 2001-10-23 | 2003-10-21 | Kemin Foods, L.C. | Finely dispersed carotenoid suspensions for use in foods and a process for their preparation |
US6936279B2 (en) * | 2002-06-18 | 2005-08-30 | Zeavision Llc | Microcrystalline zeaxanthin with high bioavailability in oily carrier formulations |
-
2006
- 2006-08-18 US US11/506,974 patent/US7435846B2/en active Active
-
2007
- 2007-03-08 WO PCT/MX2007/000024 patent/WO2008020747A1/en active Application Filing
- 2007-03-08 EP EP07747170.4A patent/EP2062570B1/en not_active Not-in-force
- 2007-03-08 JP JP2009525513A patent/JP2010502575A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2062570A1 (en) | 2009-05-27 |
EP2062570A4 (en) | 2012-07-25 |
WO2008020747A1 (en) | 2008-02-21 |
US7435846B2 (en) | 2008-10-14 |
US20080044475A1 (en) | 2008-02-21 |
JP2010502575A (en) | 2010-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2062570B1 (en) | A method for obtaining stable micro-emulsions of derivatives of oxycarotenoids of short-chain organic acids, micro-emulsions obtained, and formulation which contains these | |
CN1094326C (en) | Carotenoid preparation having mixture of beta-carotene, lycopene and xanthophyll | |
JP4988081B2 (en) | Stable lycopene powder formulations, stable lycopene aqueous dispersions, their preparation, their use and nutritional supplements containing them, animal feed, food, and pharmaceuticals and cosmetics | |
US10004670B2 (en) | Ready-to-use, stable emulsion | |
US20230063291A1 (en) | Stable carotenoid microcapsule having high bioavailability and preparation method therefor | |
US20150265638A1 (en) | Absorption of fat-soluble nutrients | |
JP5936796B1 (en) | Emulsified composition | |
CN109157510A (en) | A kind of water-soluble carotenoid preparation and the preparation method and application thereof | |
JP2009142180A (en) | Packaged beverage | |
JP2010515446A (en) | Oily composition | |
JP2009062330A (en) | Powder composition | |
US20140099386A1 (en) | Compositions and applications of carotenoids of improved absorption and bioavailability | |
JP2000106844A (en) | Water-dispersible carotenoid composition | |
US20120157547A1 (en) | Compositions and applications of carotenoids of improved absorption and bioavailability | |
JP5631941B2 (en) | Container drink | |
CA2331661A1 (en) | Use of 'nanofood' in foodstuff final products for humans and animals | |
JP5878590B2 (en) | Container drink | |
Chow et al. | The effect of dietary carotenoids of different forms: microemulsified and non-microemulsified on the growth performance, pigmentation and hematological parameters in hybrid catfish (Clarias macrocephalus× Clarias gariepinus) | |
ES2740627T3 (en) | Astaxanthin (IV) compositions | |
EP3270904B1 (en) | Astaxanthin compositions (i) | |
WO2016146803A1 (en) | Astaxanthin compositions (iii) | |
JP2009060825A (en) | Powder composition comprising oil-soluble component, and functional food product employing the same | |
EP4418865A1 (en) | Liquid composition containing a combination of vitamins a, d, e and k in a liquid matrix | |
JP2012040018A (en) | Packaged beverage | |
CN111358000A (en) | Oily composition containing carotene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090312 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120622 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A23L 1/303 20060101ALI20120618BHEP Ipc: A61K 9/48 20060101ALI20120618BHEP Ipc: A61K 31/22 20060101ALI20120618BHEP Ipc: A23L 1/275 20060101ALI20120618BHEP Ipc: A61K 9/107 20060101AFI20120618BHEP Ipc: A23L 2/58 20060101ALI20120618BHEP |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A23L 1/035 20060101ALI20130524BHEP Ipc: A61K 9/48 20060101ALI20130524BHEP Ipc: A23K 1/16 20060101ALI20130524BHEP Ipc: A23L 1/30 20060101ALI20130524BHEP Ipc: A23K 1/18 20060101ALI20130524BHEP Ipc: A61K 9/107 20060101AFI20130524BHEP Ipc: A61K 31/22 20060101ALI20130524BHEP |
|
INTG | Intention to grant announced |
Effective date: 20130617 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
INTG | Intention to grant announced |
Effective date: 20131120 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 649453 Country of ref document: AT Kind code of ref document: T Effective date: 20140215 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007034795 Country of ref document: DE Effective date: 20140227 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20140115 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 649453 Country of ref document: AT Kind code of ref document: T Effective date: 20140115 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140515 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140515 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602007034795 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140308 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 |
|
26N | No opposition filed |
Effective date: 20141016 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20140415 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20141128 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602007034795 Country of ref document: DE Effective date: 20141001 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141001 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140331 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140331 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140308 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140415 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140416 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20070308 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140115 |